 
               NCT 02556736 
 
Study ID: RST-001-CP-0001 
 
 
Title: Phase I/IIa, Open -Label, Dose- Escalation Study of Safety and Tolerability of 
Intravitreal RST -001 in Patients with Advanced Retinitis Pigmentosa (RP)  
 
                                       Protocol Date: 19- Oct-2017  
 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
1 ALLERGAN  
 
 
The following contains  proprietary information  
which is the property of Allergan, Inc. 
 
Phase I/IIa, Open-Label, Dose-Escalation Study of  
Safety and Tolerability of Intravitreal RST-001 in  
Patients with Advanced Re tinitis Pigmentosa (RP) 
 
Protocol Number:   RST-001-CP-0001, Amendment 2 
Phase: Phase 1/2a 
Name of Investigational Product: RST-001 (AGN-151597) 
Sponsor: 
 Allergan, Inc. 
2525 Dupont Drive 
Irvine, California USA 92612 +1-714-246-4500 +1-800-347-4500  
Emergency Telephone Number(s): No rth America:
Serious Adverse Event Reporting Fax Number(s): 
Allergan Medical Safety Physician 
Contact Information: 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
2 Allergan Signatory: 
Therapeutic Area Head 
Glaucoma and Retina 
Allergan – Global Drug Development  
Refer to the final page of this protocol for electronic signature 
and date of approval. 
 
 
 
The following information can be found on United States FDA Form 1572 and/or study contacts 
page and/or the Trial Master Fi le: Name and contact information of Allergan study personnel and 
Emergency Telephone Numbers; name, address,  and statement of qualifications of each 
investigator; name of each subinvestigator work ing under the supervision of the investigator; 
name and address of each reviewing Institut ional Review Board (IRB); US 21 CFR 312.23 
section 6(iii)b. 
 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
3 INVESTIGATOR SIGNATURE PAGE 
 
Investigator: 
I agree to: 
• Implement and conduct this study diligently  and in strict compliance with the 
protocol, good clinical practices and all applicable laws and regulations. 
• Maintain all information supplied by Allergan in confidence and, when this 
information is submitted to an Institutiona l Review Board (IRB), Independent Ethics 
Committee (IEC) or another group, it will be submitted with a designation that the material is confidential. 
• Ensure that all persons assisting with the study are ade quately informed about the 
protocol, the investigational product(s), and their study-related duties and functions. 
 
I have read this protocol in its en tirety and I agree to all aspects. 
 
 
 
Investigator Printed Name   Signature  Date 
  

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
 1
 1
List of T
List of F
 2
 3
3.1 
3.1.1 
3.1.2 
3.1.3 
3.1.4 
3.1.5 
3.2 
3.3 
3.4 
3.5 
3.6 
3.6.1 
3.6.2 
3.6.3 
3.7 
3.7.1 
3.8 
3.9 
3.9.1 
3.9.2 
3.10 
3.11 
3.11.1 
3.12 
3.13 
3.14 
3.14.1 
3.15 
3.15.1 
3.15.2 
3.15.3 
3.15.4 
 4
4.1 
4.2 
4.3 
4.4 
4.5 Tabl
Table of C
ables ...........
igures .........
Protocol S
IntroductioBackgroun
Retinitis piClinical feCellular paPathogenesTreatm
ent .
Adeno-AssRecombin
a
Human CliRST-001 ...NonclinicaPharmacolT
oxicology 
JustificatioRST
-001 S t
ImmunogeTreatment Objectives Primary OSecondary Study condRisks and Potential RProtection Provisions Potential BRisk BeneStudy OveStudy DesiStudy PopEligibility Early DiscT
reatments  
Identity of Dosage anMethod of Dose RatioPatient
 and e of Cont e
ontents  ........
......................................
ynopsis ........
n .................
d and Ratio n
gmentosa ( R
atures  ..........
thology .......
is ................
...................
ociated Vir u
nt AA V Vec t
nical Experi e
...................
l Studies wi t
ogy Studies  .
and Biodis t
n for Huma n
tudy Ration a
nicity of RS T
Administrati
of the Stud y
bjective:  ......
Objectives:  
uct and GC P
Benefits .......
isks ............
from Risks  .
for Injury  ...
enefits  ........
fit Analysis  ..
rview  ..........
gn ...............
ulation  .........
Criteri a .......
ontinuation o
...................
Investigatio n
d Administr a
Assigning P a
nale ............
Investigato rents 
................... .
................... .
................... .
................... .
................... .
nale ............. .
RP) .............. .
................... .
................... .
................... .
................... .
us ................ .
tors ............ .
ence with A A
................... .
th RST-001  ..
................... .
tribution St u
n Dose ........ .
ale: Optoge n
T-001 ......... .
on .............. .
y .................. .
................... .
................... .
P Complian c
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
of Patients  ...
................... .
nal Product  ..
ation ............ .
atients to D o
................... .
r Masking ....
4 ...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
AV2 Vector s
...................
...................
...................
udies ............
...................
netic Therap y
...................
...................
...................
...................
...................
ce Statemen
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
ose Groups  .
...................
...................Protoco
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
s .................
...................
...................
...................
...................
...................
y for Advan
...................
...................
...................
...................
...................
t ..................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................l RST-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
ced Retiniti s
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
s Pigmentos a
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.......4 
...... 8 
...... 9 
.....10 
.....13 
.... 13 
.... 13 
.... 13 
.... 13 
.... 13 
.... 14 
.... 14 
.... 14 
.... 14 
.... 14 
.... 15 
.... 15 
.... 16 
.... 18 
a .. 18 
.... 19 
.... 19 
.... 19 
.... 19 
.... 19 
.... 20 
.... 20 
.... 20 
.... 20 
.... 21 
.... 21 
.... 21 
.... 21 
.... 21 
.... 24 
.... 24 
.... 26 
.....27 
.... 27 
.... 27 
.... 27 
.... 27 
.... 28 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
4.6 
4.7 
4.8 
4.9 
4.10 
4.11 
4.12 
 5
5.1 
5.1.1 
5.1.2 
5.1.3 
5.1.4 
5.1.5 
5.1.6 
5.1.7 
5.1.8 
5.1.9 
5.1.10 
5.1.11 
5.1.12 
5.1.13 
5.1.14 
5.2 
5.2.1 
5.2.2 
5.2.3 
5.2.4 
5.2.5 
5.2.6 
5.2.7 
5.3 Packaging 
Handling aStudy TreaProduct AcAssessmenTreatment Prior and Study Asse
Schedule o
Informed Screening Baseline VTreatment Post InjectiDay 7 ........Month 1  ....
Month 3  ....
Month 6: PMonth 9  ....
Month 12  ..
Month 18  ..
Month 24 (Long-term DescriptioInform
ed 
Medical Hi
Concomita
Adverse EPhysical EPregnancy Blood Sam
T
reatment and Labelin g
nd Storage  ..
tment Prepa r
countability
t of Compli a
of RST-001 O
Concomitant 
ssments an d
f Procedure s
Consent and P
Visit ............
isit ..............
Visit (Day 0 )
on Visit (D a
...................
......................................
rimary End p
.........................................................
or Early Ter
Follow-up V
n of Study P r
Consent ........
story (Revi e
nt Medicati o
vent Review  
xamination ..
Test ............
ple ..............
Administratig ................. .
................... .
ration and A
................... .
ance ............ .
Overdose  ....
Therapy  ......
d Intravitreal 
s by Visit  .....
Patient Priv a
................... .
................... .
) ................. .
ay 1) ............ .
................... .
................... .
................... .
point ........... .
................... .
................... .
................... .
mination) V
Visits ........... .
rocedures  ....
................... .
ew) .............. .
ons and Pro c
................... .
................... .
................... .
................... .
on .............. .
5 ...................
...................
Administrati o
...................
...................
...................
...................
Injection  ...
...................
acy .............
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
Visit .............
...................
...................
...................
...................
cedures  ........
...................
...................
...................
...................
...................Protoco
...................
...................
on ................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................l RST-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 28 
.... 28 
.... 28 
.... 29 
.... 29 
.... 29 
.... 29 
.....29 
.... 32 
.... 32 
.... 32 
.... 33 
.... 34 
.... 34 
.... 35 
.... 35 
.... 35 
.... 36 
.... 36 
.... 37 
.... 37 
.... 38 
.... 38 
.... 39 
.... 39 
.... 39 
.... 40 
.... 40 
.... 40 
.... 40 
.... 40 
.... 43 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
5.3.1 
5.3.2 
 6
6.1 
6.1.1 
6.1.2 
6.2 
6.2.1 
6.2.2 
6.2.3 
6.2.4 
 7
7.1 
7.2 
7.3 
7.4 
 8
8.1 
8.1.1 
8.1.2 
8.1.3 
8.1.4 
8.2 
8.3 
 9
 10
10.1 
10.2 
 11
11.1 
11.2 
11.2.1 
11.2.2 
11.3 
11.3.1 
11.3.2 
11.3.3 
11.3.4 
11.3.5 
11.3.6 
 12
 13
13.1 Post Injecti
ManagemeSafety Ass
Overview 
Ocular SafSystemic SClinical MIntraocular ComplicatiOccupatioPregnancy Data Safet
Co
mpositi
Role ..........
ResponsibiEnrollment Adverse E
Definitions
Adverse ESerious AdSeverity  ....
RelationshiProcedures Procedures Efficacy A
Clinica
l M
Monitoring
Study and Data Analy
Primary (S
Secondary Measures 
o
AnatomicaStatistical Power and Baseline CSafety AnaEfficacy AOther AnalInterim AnInvestigato
Data HandData Manaon Medicati
nt of Post I nj
essments  .....
of Safety As s
ety Measure m
afety Meas u
anagement o
Inflammati o
ons of the I n
nal Safety  ....
and Exposu r
y Monitorin g
on ................
...................
lities ...........
Stopping R u
vents ...........
...................
vent .............
verse Event  
...................
p to Study D
for Reporti n
for Reporti n
ssessments  ..
onitoring St r
 ..................
Site Closure  
sis and Stat i
afety) Endp o
Endpoints  ..
f Change in 
l Endpoints R
Analysis Pla n
Sample Siz e
haracteristic s
lysis............
nalysis  ........
ysis .............
alysis ..........
r Responsib i
ling and Re c
gement Res pons ............. .
njection Intr a
................... .
sessments  ....
ments ......... .
urements ..... .
of Safety Pa r
on and Imm u
ntravitreal I nj
................... .
re to RST-0 0
g Committe e
................... .
................... .
................... .
ules ............ .
................... .
................... .
................... .
................... .
................... .
Drug or Stu d
ng Adverse E
ng a Serious 
................... .
ructure  ........ .
................... .
................... .
istical Consi d
oint ............. .
................... .
Visual func
Relating to R
ns ............... .
e Considerat i
s ................. .
................... .
................... .
................... .
................... .
ilities  .......... .
cord Keepin g
ponsibilities .
6 ...................
aocular Pres
...................
...................
...................
...................
rameters  ......
unogenicity 
njection  .......
...................
01 In Utero  .
e (DSMC)  ...
...................
...................
...................
...................
...................
...................
...................
...................
...................
dy Procedur
Events  ........
Adverse E
...................
...................
...................
...................
derations  ....
...................
...................
tion ............
Retinal Inte
...................
ions ............
...................
...................
...................
...................
...................
...................
g .................
...................Protoco
...................
sure ............
...................
...................
...................
...................
...................
Related to 
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
e ..................
...................
vent .............
...................
...................
...................
...................
...................
...................
...................
...................
grity and Su
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................l RST-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
RST-001  ......
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
rvival  ......... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 43 
.... 43 
.....43 
.... 43 
.... 43 
.... 45 
.... 45 
.... 46 
.... 46 
.... 46 
.... 47 
.....47 
.... 47 
.... 47 
.... 47 
.... 48 
.....48 
.... 48 
.... 48 
.... 49 
.... 50 
.... 50 
.... 50 
.... 50 
.....51 
.....51 
.... 52 
.... 52 
.....52 
.... 52 
.... 52 
.... 52 
.... 53 
.... 53 
.... 53 
.... 54 
.... 54 
.... 54 
.... 54 
.... 54 
.....54 
.....55 
.... 55 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
13.1.1 
13.1.2 
 14
 15
15.1 
 16
16.1 
 17
 18
 19
 20
20.1 
20.2 
20.3 
20.4 
 
 Data Quali
Source DoStudy Ter
Regulatory Ethical Co
Manageme
Protocol A
Publicatio
n
Sponsor's 
References  
AppendiceAppendix 
Appendix Protocol AProtocol Aty Assuranc e
cuments  ......
mination  .......
and Ethical 
nduct of the 
nt of Protoc o
mendments  .
 Policy  .......
Final Report  
...................
s ..................
1: Abbreviat i
2: Clinical L a
mendment S
mendment Se .................. .
................... .
................... .
Considerati
Study ......... .
ol Amendm e
................... .
................... .
................... .
................... .
................... .
ions ............ .
aboratory T e
ummary A m
ummary A m
7 ...................
...................
...................
ons .............
...................
ents and De
...................
...................
...................
...................
...................
...................
ests .............
mendment 1  
mendment 2  Protoco
...................
...................
...................
...................
...................
viations  .......
...................
...................
...................
...................
...................
...................
...................
...................
...................l RST-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 55 
.... 56 
.....56 
.....56 
.... 57 
.....59 
.... 59 
.....59 
.....59 
.....60 
.....61 
.... 61 
.... 62 
.... 64 
.... 83 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
8 List of Tables 
Table 1 Dose Escalation  .......................................................................................................... 23  
Table 2 Study Visit Schedule: Core Study Visits  .................................................................... 31  
Table 3 Study Visit Schedule: Long-term Follow-up Visits  .................................................... 32  
Table 4 Biomicroscopic Grading of Ante rior Chamber Cells and Flare  ................................. 44  
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
9 List of Figures 
Figure 1 Overview of the Treatment Schedule  ......................................................................... 23  
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
12 Clinical Study 
progress Patients will be enrolled sequentially. The decision to dose escalate will be determined with the DSMC upon review of adverse events (AE), clinical evaluations (ocular and systemic) and laboratory results. 
Monitoring of safety 
and tolerability Safety monitoring will include a combination of AE reporting, clinical evaluations (ocular and systemic), and laboratory results. 
Ocular and systemic safety monitoring will include monitoring for signs of an immune response.  
Enrollment Stopping 
rules Any Grade 3 (Common Terminology Criteria [CTC] for AEs v4.03) or greater AE considered related to the study treatment. 
Primary endpoints: 
Assessment of safety The primary endpoint is safety at 6 months from start of study treatment. The therapy will be considered safe in th e absence of any grade 3 or greater AE 
considered related to RST-001. 
Secondary endpoints The effect of intravitreal injection of RST-001 in improving visual function as measured by a series of psychophysical , electrophysiological and anatomical 
measures. 
Analysis plan The sample size for this study was chos en empirically; no formal sample size 
computations to meet power requireme nts were made. The sample size of 
approximately 3 patients for each dose group in Phase 1 are typical for dose escalation 
studies, an additional up to approximately 12 patients will be enrolled in Phase 2a for further safety and efficacy evaluation. 
Summary tables and listings of data will be provided per Statistical Analysis Plan. All 
summaries of categorical data will present frequencies and percentages. All summaries 
of continuous data will present the number of non-missing values, mean, standard deviation, minimum, median and maximum. 
 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
 3
3.1 
3.1.1 
Retinitis 
retina. It 
100,000 
conditio
inherite
RP is ge
genes hadominan
3.1.2 
Early di
progress
macula 
disease 
lost. 
Examin
as discre
attenuati o
3.1.3 
RP is pri
progress
retinal p
which inretinal g
connecti
3.1.4 
Given th
the preci
stresses Intr
Back
Reti
pigmentosa 
is estimate
individuals 
n. A similar 
d as an isolat
netically het e
ve been ide
t trait. 
Clin
sease manife
es, the visu
edema, visu
will have po
ation finding
te bone-spi c
on.  
Cell
marily a dis
es (Daiger e
igment epit
clude cell r
anglion cell
ons with the 
Path
e large num
se molecula
the photorecoduction 
kground a n
nitis pi gm
(RP) is a h e
d that the pr e
(Sohocki et a
prevalence r
ed ocular di s
erogeneous w
ntified. In th e
ical featu r
sts as night-
al field const r
al acuity (V A
or V A and m
s include ab n
ules, outer r
ular path o
ease of the r
t al., 2007 ). 
helium. Loss 
eorganizatio n
s, which co m
brain. 
ogenesis 
ber of causa t
r pathology 
eptor cells end Ratio n
entosa (R P
ereditary, sl o
evalence of R
al., 2001) w i
rate is thoug h
sease thoug h
with more t h
e U.S., RP i s
res 
blindness a n
ricts relativ e
A) is preserv e
minimal pres e
normal pig m
retinal atrop h
ology 
od photorec e
Cone photo r
of the phot o
n, disorgani z
mprise the in n
tive genes a n
of RP remai
eventually re
13 nale 
P) 
owly-progre
RP in the U
ith 10-20% 
ht to occur w
h it is a man
han forty ca
s most com
nd peripher
ely symmetr
ed until adv
erved visual 
mentary cha n
hy, optic ner
eptors whic
receptors su
oreceptors r
zation and c e
nermost lay
nd the diver
ns elusive. 
sulting in t hProtoco
ssive, neuro
nited States 
suffering se
worldwide. 
ifestation o  
usative gen
monly inher i
al visual fiel d
ically. Unle
anced disea
field. In so m
nges in the r
ve pallor an
h are gradu a
bsequently 
esults in cha n
ell loss. Eve
er of the ret
se propertie
It is likely t
he activation l RST-001-CP
degenerativ e
(U.S.) is ap p
vere vision l
RP is most f r
fmany synd r
es and perha p
ited as an au t
d defects. A s
ss complica t
se. A patient 
me instance s
etina, classi c
d retinal va s
ally lost as t h
degenerate, t
nges in the i
n in the adv a
ina, persist a
s of the prot e
hat the mole c
of cell deat h-0001 Amend m
e disease of t
proximately 
loss from th i
requently 
romes. 
ps only 50 %
tosomal 
s the disease
ted by cysto i
with advan c
s, all vision i
cally appear i
scular 
he disease 
together wit h
inner retina,
anced stage s
and maintain
eins they en c
cular pathol o
h pathways.ment 2
the 
is 
% of 
 
id 
ced 
is 
ing 
h the 
s, 
n their 
code, 
ogy 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
14 Photoreceptors and other neuronal ce lls of the retina have little or no replicative function and cell 
loss results therefore in progressive deficit. 
3.1.5 Treatment 
Currently, there is no approved drug treatment for RP. Supplemental doses of Vitamin A may 
reduce the rate of degeneration in certain i ndividuals but the effects are insubstantial 
(Rayapudi et al., 2013 ). The Argus II retinal prosthesis (a n opto-electronic implant developed by 
Second Sight Medical Products Inc., Sylmar , CA) has been approved by the FDA, on a 
humanitarian basis, for those most severely affected by RP  (Dorn et al., 2013).  
3.2 Adeno-Associated Virus 
Adeno-associated virus (AA V ) is a parvovirus with a single-stranded DNA genome 
(Muzyczka N, Berns KI, 2001 ). It re quires a helper virus to complete its replication cycle in 
culture and in humans ( Blacklow NR, Hoggan MD, 1967) . AA V does not appear to integrate in 
humans ( Schnepp BC, et al 2005 ) and has not been associated with hum an disease ( Flotte TR, 
Carter BJ, 1995 ).  
3.3 Recombinant AA V Vectors 
Recombinant AA V (rAA V) vectors are composed of a transgene expression cassette between 
inverted terminal repeats (ITRs), which guide pa ckaging of vector DNA into AA V capsids. rAA V 
vectors are non-toxic, highly efficient at tran sducing a wide variety of  non-dividing cell types, 
and persist for long periods potentially leadi ng to long-term  expression of the transgene ( Carter 
PJ, Samulski RJ 2000 ).  
3.4 Human Clinical Experience with AA V2 Vectors 
AA V2 is currently being used as the vector of  choice in multiple clinical studies around the 
world setting a precedent as a safe delivery system for gene therapy. Specifically, AA V2 has been 
used as a vector in clinical studies within the United States since 2004. To date there are no 
approved products utilizing AA V2 bu t there are a number of clinical studies that either have been 
completed or are ongoing worldwide, some of which are in the area of ophthalmology, including indications like neovascular age-related macular degeneratio n, Leber Congenital Amaurosis 
(LCA), and choroideremia. 
3.5 RST-001 
RST-001 (AGN-151597) is a gene therapy product   
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
15 3.6 Nonclinical Studies with RST-001 
3.6.1 Pharmacology Studies 
Two studies were conducted in mice, collectiv ely covering a 10-fold range of dose exposure 
from the lowest ( ) to the highest  dose ( ). The objective of these 
studies was to test the behavioral  efficacy of a single-1 µL intrav itreal injection in both eyes of 
RST-001 (dosing solutions ): (Low); (Mid);  (High)) on visual 
function in C3H/HeJ-Pde6brd1 mice ( ; hereafter “C3H”). These mice are 
homozygous for the retinal degeneration 1 mutation (Pde6brd1), which causes blindness by 
weaning age. The sighted control mice we re C3Sn.BLiA-Pde6b+/DnJ ( ; 
hereafter “C3Sn”). Behavioral assessments we re done prior to AA V2-ChR2 (RST-001) (when 
mice are ~ 8 weeks old; hereafte r “Baseline”), again starting at P120 (hereafter “Test 1”), and 
finally at 6 months post injection (hereafter “Test 2”). Viral in jections were done around 9 weeks 
old.  
There were no injection-related complications and no animals died during the perioperative time 
period. At the two-month time point, there was ev idence of improved visual function in rd1 mice 
treated with RST-001 at all dos es ( ) 
evaluated as compared with vehicle injected mi ce, based upon optokinetic responses. The highest 
dose ( ) also showed efficacy for visual placement responses. These effects were 
investigated in the high dose at 6 months post injection, but were not reproduced. However, 
electrophysiological measures appear to have verified ChR2-driven light responses at the 
ganglion cell layer 10 months post injection. Non-GLP safety observations were also conducte d in conjunction with this pharmacology study.  
RST-001 produced no signs of test article rela ted effects on body weights, food consumption, 
clinical observations or during ophthalmic examinations. There were no gross lesions at terminal 
necropsy related to the test article treatment . Histological evaluations were conducted for 
animals in the control and highest dose group. No  test item-related microscopic findings were 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
16 noted in the tissues examined (brain, epididymis, eye, heart, kidney, liver, lung, mandibular and 
mesenteric lymph nodes, optic nerve, paro tid salivary gland, spleen and testis). 
3.6.2 Toxicology and Biodistribution Studies 
Two nonclinical GLP toxicology and biodistribution studies have been completed in two species, 
beagle dogs and mice. The objectives of both stud ies were to determine the potential ocular 
toxicity of RST-001 when given by a single intrav itreal injection and to evaluate the potential 
reversibility of any findings within 99 days of treatment.  
The following parameters and end points were evaluated: clinical signs, body weights, food 
consumption, ophthalmology, clinical pathology pa rameters  
 
, gross necropsy findings, organ weight s, and histopathologic examinations, and 
biodistribution.   

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
17 3.6.2.2  Mice Study 
The purpose of this study was to evaluate the toxici ty of the test article, RST-001, when given as 
a single 1 µL intravitreal injection in the right eye to C3H/HeJ-Pde6brd1 mice.   
Mice historically have been used in safety evaluation studies and this particular strain is a disease 
model for advanced RP, the indication of RST-001.  
There were 64 mice per dose group and 4 dose gr oups. Actual doses verified were: vehicle 
(control); (Low),  (Mid), a nd (High) vg/eye of RST-001.  After 
dosing, animals were observed post dose for at leas t 29 (interim sacrifice) or 89 days (terminal 
sacrifice). There were 16 animals/se x/group at each terminal sacrifice. 
There are no signs of test article related eff ects on body weights, food consumption, and clinical 
observations or during ophthalmic examinations through Week 4 of the dosing phase. There were 
no gross lesions at any of the terminal necropsy in tervals that appear to be related to the test 
article treatment.  There were no signs of overt ti ssue damage due to direct toxicity of the test 
item and no cellular immune or humoral response to RST-001 was detected at any dose level. 
RST-001 was present at the highest level in the ri ght eye and optic nerve of all animals tested. 
RST-001 was also detected just above the minimu m level of detection

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
18 within the hindbrain and spleen. Dose-dependent  minimal to moderate ChR2 immunolabeling 
occurred in the right treated eye of animals given ; minimal ChR2 
immunolabeling was also present in the right  optic nerve of some animals with ChR2 
immunolabeling in the right eye. 
In conclusion, administration of RST-001 by a singl e intravitreal injection at a 10-fold difference 
in nominal doses  resulted in no dose-related effects. RST-001 had minimum biodistribution 
systemically and was expressed in the retina. 
3.6.3 Justification for Human Dose 
The doses and injection volume have been calcul ated by allometric scaling from pre-clinical 
animal studies.  Vitreous humor volume was the scal ing factor across species. In general, scaling 
of the vitreous volume from mice and dogs to humans is 1:100 and 1:2, respectively.  Two 
nonclinical toxicology studies were conducted in the dog and mouse. The safe intravitreal doses 
in the dog ranged from . For the mouse, the sa fe intravitreal doses 
ranged from .  Two nonclinical pharmacology studies demonstrated 
efficacy and safety in the mouse at a dose range of  in a dose range 
comparable to the toxicology study. Based on thes e studies, the expected  safe dose range in 
humans is between  and . The dose range in this study ( to 
 of RST-001) is based on the more conservative exposure in the dog, inclusion of 
potentially efficacious doses, the ability of the manufacturer to concentrate investigational 
product, and a safe injection volum e of  per eye in humans.  
3.7 RST-001 Study Rationale: Opt ogenetic Therapy for Advanced 
Retinitis Pigmentosa 
RST-001 is a gene therapeutic treatment that rende rs cells in the retina se nsitive to light. This 
light sensitivity is conveyed to the brain and is a photoreceptor substitute in conditions such as 
advanced RP where the normal light sensitive cells are lost. 
The disease of advanced RP results in the irreve rsible loss of photoreceptors, which are the only 
cells in the retina that are able to  convert the light entering the eye into an electrical signal that 
can be relayed to the brain and interpreted as vision. Although these cells degenerate, many of 
the other neuronal cell types that receive input fro m the photoreceptors persis t. In particular, the 
innermost retinal cells, the retinal ganglion cells (RGCs) survive in significant numbers late into 
the disease and axons from these cells rema in connected directly to the brain.  
Direct electrical stimulation of  the RGCs using surgically-imp lanted electronic devices have 
provided a proof of concept that visi on can be mediated through these cells. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
19 RST-001 delivers a gene encoding a photo switc h, channelrhodopsin-2, to the RGCs. When 
expressed, the channelrhodopsin-2 protein can depol arize in response to li ght thus generating a 
signal that is transmitted to the brain. The co mponents of RST-001 are shown in detail above. 
The study is composed of two phases. An initial  dose-escalation study (Phase 1) is proposed 
whereby three dose levels of RST-001 will be studie d in three separate groups of adult patients 
with advanced disease. Phase 1 is aimed at determining a single dose of the experimental 
treatment which is safe and well tolerated, to furt her evaluate in a fourth group of patients. If the 
Data Safety Monitoring Committ ee (DSMC) considers the safety  and tolerability of RST-001 
satisfactory in the first phase, then the study ma y proceed to Phase 2a. Phase 2a is aimed at 
obtaining additional safety data at the maximum to lerated dose. An additional objective of Phase 
2a is to provide important additional clinical da ta to guide the design of future efficacy studies. 
3.7.1 Immunogenicity of RST-001 
Preclinical data indicated that no cellular or humoral immune response to RST-001 was detected 
at doses up to  in mice and dogs, respectively. In this study, 
evidence of an immune response to the produc t will be carefully assessed by monitoring for 
systemic measurement of humoral and cellular immunity. Local or systemic immune suppression 
may be initiated if clinically indicated. 
3.8 Treatment Administration 
RST-001 will be administered by intravitreal in jection as specified in the Study Procedures 
Manual. The injection volume is .  
Prior to study treatment administration, the stud y eye of each patient will be prepared using a 
standard protocol as described in the Study Procedures Manual. 
3.9 Objectives of the Study 
3.9.1 Primary Objective: 
To evaluate the safety of a single intravitreal injection of RST-001. 
3.9.2 Secondary Objectives : 
1. To establish the maximum tolerated dose of RST-001. 
2. To evaluate the preliminary efficacy of RST-001 in patients with advanced RP. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
20 3.10 Study conduct and GCP Compliance Statement 
This study will be conducted in compliance wi th the protocol approved by the Institutional 
Review Board (IRB), and according to Good Clini cal Practice (GCP) standards.  No deviation 
from the protocol will be implemented without the prior review and approval of the IRB except 
where it may be necessary to eliminate an immediate hazard to a research patient.  In such case, 
the deviation will be reported to  the IRB as soon as possible. 
3.11 Risks and Benefits 
3.11.1  Potential Risks 
The risks associated with this st udy can be divided into those relate d to the intravitreal injection 
of RST-001, the RST-001 treatment and study procedures. 
3.11.1.1  Intravitreal Injection 
These risks are well recognized and include transient conjunctiv al hyperemia and hemorrhage at 
the injection site. Serious complications such as retinal tears/holes, retinal  detachment, vitreous 
hemorrhage and endophthalmitis are uncommon or rare but may result in reduced vision and may require surgical intervention. 
3.11.1.2  RST-001 Treatment 
The risks of intravitreally-administered RST- 001 are not known. Potential risks include an 
immune response, which may result in ocular inflammation and the associated consequences. 
3.11.1.3  Study Procedures 
The risk from the tests performed in this study ca rry minimal risks and mostly relate to the need 
for pupillary dilation, which typically results in temporary blurred vision and increased light sensitivity. On occasion, a corneal abrasion can result from the use of the 
3.12 Protection from Risks 
The RST-001 drug product has been manufactured in comp liance with current Good 
Manufacturing Practice (cGMP). Exte nsive testing has been performed to ensure infective agents 
and pathogens are not present. 
Intravitreal injection of RST-001 will be pe rformed in the operating room under aseptic 
conditions by qualified staff in accordance with the Study Procedures Manual.  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
21 After the procedure, each patient will be care fully monitored for complications. Evidence of an 
immune response to RST-001 will be m onitored (refer to Section 6.2.1).  
The conduct of this study will be overseen by the DSMC.  
3.13 Provisions for Injury 
Any complications arising post injection will be  managed in accordance with the investigator’s 
standard of care. 
It is not possible for RST-001 to be re moved from the eye after injection.  
3.14 Potential Benefits 
Patients may not benefit directly fr om the study. It is theoretical at  this time as to whether any 
visual benefit will be afforded by RST-001. The primary objective of this particular study is to 
establish safety of RST-001.  
3.14.1  Risk Benefit Analysis 
Since RST-001 has not yet been shown, in humans, to be efficacious, investigators and patients 
will need to weigh carefully the risks shown above with the theoretical possi bility of improved or 
preserved visual function. 
3.15 Study Overview 
3.15.1   Study Design 
This is an open-label, dose-escalation study to ev aluate the safety and to lerability of RST-001 
administered as a single intravitreal in jection in patients with advanced RP.  
3.15.1.1  Enrollment Phase 1 
Three groups of patients (A, B, C, each compri sing of approximately but no less than three 
patients) will be enrolled in this study.  
Approximately 3 patients in Group A will receive the lowest dose of RST-001 (LOW). The safety 
and tolerability of RST-001 will be assessed in th e first patient for a mi nimum of one month (to 
include Month 1 Visit). If the DSMC considers th e safety and tolerability of the first patient 
satisfactory and the enrollment stopp ing rules have not been met, then the remaining patients in 
Group A can be enrolled and receive treatment.   

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
22 If the DSMC considers the safe ty and tolerability of Group A satisfactory and the enrollment 
stopping rules have not been met after a minimum assessment of one month (to include Month 1 
Visit) from the last treatment group, then appr oximately 3 patients in Group B may be enrolled 
and receive a higher dose of RST-001 (MID) fo llowing the same guidelines and treatment 
schedule.  
Similarly, if the DSMC considers the safety and tolerability of Group B satisfactory and the 
enrollment stopping rules have not been met after a minimum assessment of one month (to 
include Month 1 Visit) from the last treatment group, then ap proximately 3 patients in Group C 
may be enrolled and receive the highest dose of  RST-001 (HIGH) following the same guidelines 
and treatment schedule. 
After completion of the 2-year core study visits , each patient will be enrolled in a long-term 
follow-up for an additional 13 years to m onitor the long-term safety of RST-001. 
3.15.1.2  Enrollment Phase 2a  
If the DSMC considers the safety and tolerabi lity satisfactory and the enrollment stopping rules 
have not been met after a minimum assessment of  one month (to include Month 1 Visit) from 
treatment of the final patient in Groups A, B, or C, then the sponsor may elect to start enrollment 
in the second cohort of patients.  In Phase 2a, up to approximately 12 patients may be enrolled 
and receive RST-001 at the maximum tolerated dose. 
• If the DSMC considers the data from Phase 1, in their opinion, to be indicative of a 
treatment benefit for visual acuity/function, then approximately 6 patients will be 
enrolled in Phase 2a and follow the same eligibility criteria as Phase 1. 
• If the DSMC considers the data fr om Phase 1, in their opinion, to not be indicative of a 
treatment benefit, then approximately 12 patients will be enrolled in Phase 2a. 
o 6 patients must have V A of no-bette r-than hand motion in the study eye. 
o 6 patients must have V A in the study eye to range from no-worse-than count fingers to 20/200 vision. 
A schematic providing an overview of the treatment schedule is illustrate d in Figure 1 , and the 
dose-escalation cohorts are illustrated in Table 1  below.  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
23 Figure 1 Overview of the Treatment Schedule 
 
 
Table 1 Dose Escalation 
Phase  Group  Number of patientsa Intravitreal Injection 
Vector concentration  Volume 
 
1 A 3 LOW   
B 3 MID   
C 3 HIGH   
2a  6-12b Choice of dosec from 
groups A, B, or C   
a Up to approximately 21 patients w ill be enrolled in this study. 
b Number of patients is dependent upon whether or not the DSMC determines that, in their opinion, a treatment 
benefit for visual acui ty/function has been observed in Phase 1. 
c The maximum tolerated dose. 
 
After completion of the 2-year core study visits , each patient will be enrolled in a long-term 
follow-up for an additional 13 years to m onitor the long-term safety of RST-001. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
24 3.15.2  Study Population 
The study population consists of pa tients with advanced RP  
 
 This patient group is co nsidered to be a suitab le population to assess 
safety and tolerability in this Phase 1 study.  
 
  
Up to approximately 21 patients wi ll be enrolled in this study.  
3.15.3  Eligibility Criteria 
3.15.3.1  Inclusion Criteria 
The following are requirements for entry in the study:  
General Inclusion Criteria:  
1. Male or female patients, ≥ 18 years of age at time of informed consent 
2. Patient has provided written informed cons ent and written Authorization for Use and 
Release of Health and Research Study Inform ation have been obtained prior to any study 
related procedures 
3. Patient has the ability to understand and willingness to follo w study instructions and is 
likely to complete all required visits and procedures 
4. Women of childbearing potential must have a negative pregnancy test at Screening and at 
Baseline, and agree to use an effective form of  contraception, or be surgically sterile or 
post menopausal (defined as last menstrua l period greater than two years prior to 
Baseline). Acceptable methods of contracep tion include hormonal contraception (i.e., 
birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, 
barrier methods (diaphragm, condom) with sp ermicide, or surgical sterilization (tubal 
ligation) 
5. Males must use two forms of contracepti on (including one barrier method for three 
months following study treatment administration if their partner is of child-bearing 
potential), or must be surgically sterile 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
25 Ocular Inclusion Criteria: 
Phase 1 and Phase 2a 
1. Diagnosis of advanced RP defined as: 
3.15.3.2  Exclusion Criteria 
Patients will not be excluded if the molecular diagnosis underlying their RP is not known or if 
there is presence of macular edema due to advanced RP.  
However, any one of the following will exclude patients from being enrolled into the study: 
General Exclusion Criteria:  
1. Participation in any investiga tional drug or device study within six months prior to Day 0; 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
26 4. Females who are pregnant, nursing, planning a pregnancy during the study or who are of 
childbearing potential not using a reliabl e method of contraception during their 
participation in the study  
5. History or current evidence of hypersensitivi ty to any component of the study treatment, 
medications, or diagnostic agents used in the study 
8. Any other condition that would not allow the potential patient to complete follow-up 
examinations during the course of the study and, in the opinion of th e investigator, makes 
the prospective patient unsuitable for the study  
3.15.4  Early Discontinuation of Patients 
Patients may voluntarily withdraw from the study at any time or for the following reasons:  
a) Due to an adverse event (AE) 
b) If deemed necessary by the inves tigator or the sponsor that it  is unsafe for the patient to 
continue in the study  
When possible, the decision to withdraw a pati ent from study treatment or the study should be 
discussed with the sponsor. Notification of early patient discontinuation from the study and the 
reason for discontinuation will be clearly docum ented on the appropriate Case Report Form 
(CRF). 
In the case of a withdrawing patient, every reasonable attempt will be made to complete a final 
early termination visit (as shown in the study visi t table). Patients who withdraw from the study 
prior to receiving the stu dy treatment may be replaced. 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
28 injection. In order to be safe and conservative but also balanced  with the potential for delivering 
an active dose, Allergan proposes  that the LOW initial starting dose for the first-in-human study 
be  of this dose, . The MID dose will be  of the HIGH dose,  
 
Dose escalation will proceed accordin g to Table 1 , only after review by the DSMC (see Figure 1 , 
above). Three doses have been chosen with the safety as the priority but will provide a good 
opportunity to observe biological effect. 
The rationale for the dosing schedule is once ag ain based primarily on patient safety. Thus, at 
each dose a single patient will receive treatment followed by an intensive period of observation 
for any evidence of AEs prior to dosing the remain ing two patients in the group. The safety and 
tolerability and optimal single dose of RST-001 will therefore be established in Phase 1. Phase 2a 
patients will receive a single intravitreal inject ion of RST-001 at the maximum dose tolerated by 
Phase 1 patients. 
4.5 Patient and Investigator Masking 
This is an open-label study so that patients a nd investigators will know which eye is treated and 
what dose of RST-001 was given. 
4.6 Packaging and Labeling 
Correct product identity, labeling and patient spec ificity will be assured by the use of standard 
operating procedures in accordance with FDA regulations. These operating procedures will 
include identifiers to ensure correct labeling to identity study treatm ent throughout manufacture, 
handling and administration. 
4.7 Handling and Storage 
The study treatment RST-001 is provided  
Please 
refer to the Study Procedures Manu al for additional information. 
4.8 Study Treatment Preparation and Administration 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
4.9 
Study tr e
applicab
regulato
in the st
RST-001
docume
limited t o
study sit e
mainten
designat
the cour
the com
4.10 
DeviatioSuch de
review b
4.11 
There is 
4.12 
During t h
over-theanticoag
 5
Patients criteria 
authoriz
assess elPro
eatment will 
le regulator
ry and instit
udy who me
 will only b
nt. Study tre
o the investi
e personnel 
ance. In acc
ed study sit e
se of the stu
pletion of pa
Asse
ns with resp
viations will 
oard and th
Trea
no known t
Prio
he course o  
-counter me
ulants prior 
Stu
diagnosed 
will be invit
ation, patien
igibility for duct Acco u
be shipped t
y requireme n
utional requ i
et the eligib i
e administe r
atment must 
gator and a u
is responsib l
ordance wit h
 personnel m
dy.  All stud y
tient enroll m
ssment of 
ect to dosag
be immedi a
e FDA, as a p
tment of R
reatment in t
r and Co n
fthe study, p
dications th a
to treatment
dy Assess m
with advance d
ed to partici p
ts will unde r
the study.  untabilit y
to the site a f
nts. RST-00 1
irements.  R S
ility criteria a
red in accor d
be stored i n
uthorized st u
le for study t
h all applica b
must mainta i
y treatment m
ment.   
Complia n
e and admi n
ately reporte d
ppropriate. 
RST-001 O
he event of a
ncomitant 
atients will b
at are not ex c
, and immu n
ments and I
d RP and w h
pate in this s t
rgo a compl e
29 fter receipt 
1 study treat m
ST-001 will 
and who ha v
dance with t
n a secure te m
udy site pers
treatment a c
ble regulato r
in study trea
must be ret
nce 
nistration wi l
d to Allerga
Overdose
an overdose 
Therap y
be allowed 
cluded in th e
nosuppressi
Intravitr
ho are eligib
tudy. After 
ete physical Protoco
of required 
ment will b e
only be ad m
ve signed th
he surgical p
mperature-c
onnel. The i
ccountabilit y
ry requirem
atment acco u
urned to Alle
ll be docum e
n, the medic
of RST-00
to continue 
e protocol (i
ve therapy).
eal In jectio
ble based on 
obtaining in
examinatiol RST-001-CP
documents i n
e handled in 
ministered to
e informed c
procedure d e
ontrolled ar e
nvestigator o
y, reconcilia t
ents, the inv e
untability re c
rgan or Alle r
ented by the 
al monitor, t
1. 
taking presc r
.e., antiplat e
on 
inclusion a n
formed cons e
n and labora t-0001 Amend m
n accordanc e
accordance 
 patients en r
consent for m
escribed in t h
ea with acce s
or designate d
tion and rec o
estigator or 
cords throug h
rgan design e
investigato r
the instituti o
ribed and 
elets and 
nd exclusion 
ent and 
tory testing tment 2
e with 
with 
rolled 
m. 
his 
ss 
d 
ord 
hout 
ee at 
r. 
onal 
to 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
30 Patients who meet inclusion criteria will be consid ered eligible for study entry and will receive a 
single intravitreal inject ion of RST-001. Following RST-001 administration (Day 0) patients will 
be assessed on the first po st injection day (Day 1). 
The visit schedule includes: 
• Core study visits: Twelve visits are pla nned over 24 months, including Screening and 
Baseline visits, Day 0, Day 1, Day 7, and Months 1, 3, 6, 9, 12, 18, and 24. 
• Long-term follow-up: After completion of the Month 24 visit, each patient will 
participate in a long-term follow-up study for a total of an additional 13 years. These 
visits include yearly office visits for 5 year s (Months 36, 48, 60, 72, and 84) and yearly 
teleconference interviews for 8 years (Months 96, 108, 120, 132, 144, 156, 168, and 180). 
Core study visits are described in Table 2  and long-term  follow-up visits are described in Table 3 . 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
31 Table 2 Study Visit Schedul e: Core Study Visits 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
32 Table 3 Study Visit Schedule: Long-term Follow-up Visits 
5.1 Schedule of Procedures by Visit 
Please refer to Table 2  and Table 3  for a schematic of the schedule of visits and procedures. 
5.1.1 Informed Consent and Patient Privacy 
The study will be discussed with the patient and patient’s impartial witn ess or legally acceptable 
representative. A patient wishing to participate must give informed consent and authorization 
prior to any study-related procedur es. The patient must also give  authorization (U.S. only) and 
other written documentation in accordance with  the relevant country and local privacy 
requirements (where applicable) prior to any stud y-related procedures or change in treatment. 
Each patient that provides informed consent and assent will be assigne d a patient number that 
will be used on patient documentation throughout the study. 
5.1.2 Screening Visit  
Prospective patients will be screened for eligibil ity up to 45 days prior to enrollment and the 
procedures will be performed as specified below. If convenient, the Screening and Baseline visits 
may be combined. 
It is the investigator’s responsib ility to review the results of a ll laboratory tests as they become 
available. This review will be documented by the investigator’s dated signature on the laboratory 
report. For each abnormal laborato ry test result in which the value of the test lies outside the 
normal range (see Appendix 2 f or reference values), the investigator needs to ascertain if this is 
an abnormal (ie, clinically significant) result fo r the individual subject. The investigator may 
repeat the laboratory test or request additional tests to verify the results of the original laboratory 
tests. If the laboratory value is determined by the investigator to be clinically significantly 
abnormal for that subject, the subjec t will be excluded from the study.  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
33 Records will be maintained of those individuals who are screened but do not meet the eligibility 
criteria for participation in the study. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
34                                                  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
35 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
36 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
37 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
38 5.1.14  Long-term Follow-up Visits 
Patients completing the Month 24 visit will participate in long-term follow-up visits. Patients 
will be asked to report any AEs that occur during this 13-year follow-up period. At Months 36, 
48, 60, 72, and 84, patients will undergo the following study assessments conducted at yearly 
clinic visits: 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
39 The procedures for these assessments will be the same as they were for the core study 
assessments. 
5.2 Description of Study Procedures 
5.2.1 Informed Consent 
During the Screening visit, prospective patients  will be invited to provide written informed 
consent prior to any screening evaluations. An investigator or study coordinator will provide a 
full explanation of the study, including potential  risks of participation and that they may 
withdraw from the study at any time and fo r any reason without jeopa rdizing their future 
treatment, and an investigator will provide answ ers to all questions raised by the prospective 
patient. For those with low vision, a verbal cons ent will be read out. After ensuring that all 
questions have been answered, written documentation of the informed consent decision will be obtained and the consent form will be countersigned by a witness to indicate informed consent 
was obtained.  
No study-related procedures will be performed un til after informed consent/assent is obtained.  
5.2.2 Medical History (Review)  
These will comprise: 
• Documentation of presenting co mplaints, and history thereof 
• Ocular medical and surgical history 
• General medical and surgical history 
• Current medication use (ocular and other) 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
40 5.2.3 Concomitant Medications and Procedures 
All medications and procedures will be recorded on the eCRF. If the permissibility of a specific 
medication/treatment is in question, the investigator is to contact Allergan. 
5.2.4 Adverse Event Review 
All AEs will be recorded at each study visit. 
5.2.5 Physical Examination 
A complete physical examination will be performe d  
 
 
 
 
Symptom-specific examinations may be carried out and recorded during the study as needed. 
5.2.6 Pregnancy Test 
Women of childbearing potential will undergo blood serum beta-hCG testing, to be analyzed at 
the site’s preferred certified laboratory. 
5.2.7 Blood Sample 
A venous sample will be collected from a peripher al vein and laboratory tests will be conducted 
at the preferred certified laboratory. 
Blood sample testing will include  
 
 
 
  
Instructions for shipping venous blood for immu nological analysis are detailed in the Study 
Procedures Manual. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
41 5.2.15  Complete Ophthalmic Examination 
A complete ophthalmic examination will be pe rformed in both eyes at the Screening and 
Baseline visits and at each visit after study tr eatment administration.  The examination will 
include  
 
 
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
42 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
5.3 
RST-001
Manual. 
Prior to 
standard 
5.3.1 
Topical 
standard 
5.3.2 
The inveintraocu
acetazol
 6
6.1 
Safety asystemic 
6.1.1 Trea
 will be ad
 
study treatm
protocol as 
Post 
corticosteroi
of care. 
Man
stigator sha
lar pressure 
amide or ant
Safe
Ove
ssessments i
safety. 
Ocutment Ad m
ministered b y
ent adminis t
described i n
Injection 
d treatment m
agement o
ll have the a b
and may us e
erior chamb
ty Assess m
rview of S a
n this study c
lar Safet y ministrati
y intravitrea l
tration, the s
n the Study P
Medicati o
may be giv e
of Post In j
bility to det e
e any combi n
er paracent e
ments 
afety Asse
can be divi d
Measure m
43 on 
l injection a
tudy eye of 
Procedures 
ons 
en to the inj e
jection In
ermine the o
nation of to p
esis in order 
essments 
ded into mea
ments Protoco
s specified i n
each patien
Manual.  
ected eye ac
traocular 
ptimum ma
pical IOP-lo
to normaliz
sures of ocl RST-001-CP
n the Study P
t will be pre p
cording to t h
Pressure 
nagement o f
wering med i
e the intrao c
ular safety a n-0001 Amend m
Procedures 
pared using t
he investigat o
f a raised 
ications, ora l
cular pressu r
nd measures ment 2
the 
or’s 
l 
re. 
of 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
44 6.1.1.2  Ocular Inflammation 
Owing to the potential for intraocular inflammati on (as noted in the preclinical dog study) or 
immunogenicity, signs of ocular inflammation will be carefully monitored throughout the study 
and reported to the DSMC.  Active inflammation of the anterior chamber, vitreous and 
retina/choroid will be documented in the case report forms according to recognized international 
criteria shown in Table 4 , below.  Additional investigations,  
 may be performed at the discretion of  the investigator according to clinical findings 
and accepted standards of care. 
Table 4 Biomicroscopic Grading of Anterior Chamber Cells and Flare  
This is compliant with the standardizati on of uveitis nomenclature [SUN] working group 
(Jabs et al., 2005). 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
45 6.1.2 Systemic Safety Measurements 
1. Patient-reported and investigator-reported adverse events (AEs) 
2. Physical examination findi ngs including vital signs 
3. Findings of blood and serum laboratory testing 
4. Findings of immunological testing 
6. Other clinical and laboratory testing performed by the invest igator(s) based upon clinical 
observation, such as: 
• Vital signs 
• Clinical safety laboratory parameters 
• Immune response to RST-001 administration as  measured by the testing detailed in 
Section 6.2.1 below . 
6.2 Clinical Management of  Safety Parameters  
The need for additional clinical evaluations, asse ssments and visits shall be determined by the 
investigator(s) in accordance with accepted c linical practice and standards of care, where 
applicable. All activity will be recorded in the patient’s source documentation.  
Adverse events definitions and reporting requirements can be found in the Section 8.1 below. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
46 6.2.1 Intraocular Inflammation and Immunogenicity Related to RST-
001 
During the study, evidence of immune response to RST-001 will be monitored by systemic 
measurement of humoral and cellular immunity as follows: 
6.2.2 Complications of the Intravitreal Injection 
The complications of intravitr eal injection commonly include m ild conjunctival hyperemia and 
subconjunctival hemorrhage. Other uncommon co mplications include endophthalmitis, retinal 
tears/breaks/detachment, choroidal, vitreous and retinal hemorrhage.  
In all instances, management of these complications will be determined by the investigator in 
accordance with his/her practice and st andard-of-care, where applicable. 
6.2.3 Occupational Safety 
The consequences of exposure of clini cal personnel to the RST-001 drug are unknown. 
Precautions will be taken to avoi d any exposure to the RST-001 product. No antidote is available 
for the RST-001 drug product. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
6.2.4 
Females 
Females 
participa
study, th
sponsor w
pregnant pregnan
The pote
 7
7.1 
An inde
from the 
statistici
7.2 
The pri
the stud
resolvin
agreed s
7.3 Preg
who are pre
of chil d-be
tion in the s
e patient wi l
within 24 h
during the 
cy test at M
ntial effects 
Dat
Co
pendent Dat
study. The 
an(s) with e
Role 
mary role of 
y. The DSM
g any issues 
chedule for 
Resnanc y and
gnant at the 
aring potenti a
tudy.  In the 
l continue t o
ours of beco m
course of th e
onth 24 or e a
of in utero e
a Safety M
mposition 
a Safety Mo n
members of t
xperience in 
the DSMC i s
C will revie w
that may ari
reviewing d a
ponsibiliti ed Exposu r
Screening a
al are requi r
event that a 
o be followe
ming aware t
e study.  Fe m
arly termina t
exposure to R
Monitorin g 
nitoring Co m
the DSMC w
this field o f 
s to ensure t h
w the gener a
se. The co m
ata will be d e
es 
47 re to RST-
and/or Basel
red to maint
female bec
d in the stu
that a femal
male patient
tion visit. 
RST-001 ar e
Committ
mmittee (D
will compri
fresearch. 
he protectio
al progress a n
mposition an
etailed in th eProtoco
001 In Ute
ine visit wil
ain contrace
omes pregn
dy. The inve s
e patient or f
s of childbe a
e not known
ee (DSM
SMC) will b
se ophthalm o
n and safety 
nd conduct 
d responsibi
e DSMC Cl RST-001-CP
ero 
l be exclude d
ption durin g
ant during t h
stigator sho u
female part n
aring potenti a
. 
C) 
e formed to m
ologists, ph y
 of patients p
of the study 
lities, toget h
harter. -0001 Amend m
d from the s
g their 
he course of t
uld notify th e
ner becomes 
al will requi r
monitor the 
ysicians and 
participatin g
and assist i n
her with the ment 2
tudy.  
the 
e 
re a 
data 
g in 
n 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
7.4 
Enrollm
includin
the follo w
 8
Adverse 
events o
8.1 
8.1.1 
An adve
patient a
relations
unintend
associat
medicin
be asses
Note:  A
whether Enr
ent will be s
g causality t
wing events
Adv
events occu
ccur, the firs
Defi
Adv
rse event is 
dministered 
hip with thi
ed sign (inc
ed with the 
al (investiga
sed regardle
dverse even
or not the pollment St o
uspended p e
o determine 
:  
erse Even t
rring during
t concern w i
nitions 
erse Even t
any untowa r
a pharmace u
s treatment.  
luding an a b
use of a med i
tional) prod u
ss of the ad m
ts must be c o
atient has beoppin g Ru
ending a co m
the appropr i
ts 
 the study w
ill be the sa f
t 
rd medical o c
utical produ c
An adverse 
normal lab o
icinal (inves
uct.  In addi t
ministration o
ollected onc e
en administ e
48 ules  
mplete safet y
iateness of 
will be recor
fety of the st
ccurrence i
ct and that 
event can t
oratory findi
tigational) p
tion, during 
of a pharma
e informed 
ered study tProtoco
y review by t
continuing d
ded on an a d
udy partici
n a subject o r
does not nec e
herefore be 
ng), sympto
product, wh
the screenin
ceutical pro d
consent has 
reatment. l RST-001-CP
the sponso r o
osing in the 
dverse event 
pants.  
r clinical in v
essarily hav e
any unfavor a
m, or diseas e
ether or not r
g period, ad v
duct.   
been obtain e-0001 Amend m
of all patien t
occurrence o
CRF.  If ad v
vestigation 
e a causal 
able and 
e temporall y
related to th e
verse event s
ed, regardle sment 2
ts 
of 
verse 
y 
e 
s will 
ss of 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
49 Progression of treatment indicati on including new or worsening of anticipated clinical signs or 
symptoms, which are collected as clinical ef ficacy variables and assessed as unequivocally 
associated with the disease progression and/or lack of efficacy, should NOT be reported as 
adverse events unless the disease progression is greater th an anticipated in the natural course of 
the disease. 
Adverse events will be assessed, documented, and recorded in the CRF throughout the study (ie, 
after informed consent has been obtained).  At eac h visit, the investigator will begin by querying 
for adverse events by asking each patient a genera l, non-directed question such as “How have 
you been feeling since the last visit?”  Directed questioning and examination will then be done as 
appropriate.  All reported adverse events will be documented on the appropriate CRF.   
8.1.2 Serious Adverse Event 
A serious adverse event is any adverse event oc curring at any dose that results in any of the 
following outcomes:  death, congenital anomal y or birth defect, significant disability, 
hospitalization, or life threatening.  Important medical events that ma y not result in death, be life-
threatening, or require hospita lization may be considered a serious adverse event when, based 
upon appropriate medical judgment, they may jeopa rdize the patient or patient and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  
Allergan considers all cancer adverse events as serious adverse events.  In addition, Allergan 
considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
Preplanned surgeries or procedures for pre- existing, known medical conditions for which a 
patient requires hospitaliza tion is not reportable as a serious adverse event. 
Any preplanned surgery or proced ure should be clearly documented in the site source documents 
by the medically qualified investigat or at the time of the patient’s entry into the study.  If it has 
not been documented at the time of the patien t’s entry into the study, then it should be 
documented as a serious adverse ev ent and reported to Allergan. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
50 8.1.3 Severity 
A clinical determination will be made of the intensity of an adverse event.  The severity 
assessment for a clinical adverse event must be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated. 
Moderate Discomfort enough to cause interference with usual activity. Severe Incapacitating with inability to work or do usual activity. 
8.1.4 Relationship to Study Drug or Study Procedure 
A determination will be made of the relationship (if any) between an adverse event and the study 
drug or study procedure, as applicable.  A causa l relationship is present if a determination is 
made that there is a reasonable possibility that the adverse event may have been caused by the 
drug or study procedure. 
A study procedure occurring duri ng the screening/baseline peri od can include a study required 
diagnostic procedure. For treatment-related adverse events, the investigator will note on the CRF whether the event is 
related to the study drug, and/ or the injection procedure. 
8.2 Procedures for Reporting Adverse Events 
Any adverse event must be recorded on the appropriate CRF. 
All adverse events that are drug- related and unexpected (not listed as treatment-related in the 
current Investigator's Brochure) must be report ed to the governing IRB as required by the IRB, 
local regulations, and the governi ng health authorities.  Any ad verse event that is marked 
“ongoing” at the exit visit must be followed-up as appropriate. 
8.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed consent) 
and for at least 28 days after study exit must be immediately reported but no later than 24 hours 
after learning of a serious adverse event.  Serious adverse events must be reported to Allergan (or 
Agent of Allergan) as listed on the Allergan St udy Contacts Sheet and r ecorded on the serious 
adverse event form.  All patients with a seriou s adverse event must be followed up and the 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
outcome
requeste
In the ev
1. 
(
n
2. 
p
3.
 P
sg
S
c
a
e
4. 
P
l
 9
A variet y
order to s reported.  
d informatio
ent of a seri
Notify Aller
contact deta
umbers and 
Obtain and 
medical judg
atient. 
rovide Alle
erious adve
iven (eg, m
ummarize r
linical cour
lternative e
vent was or 
romptly inf
ocal regulati
Effic
y of paramet
identify a siThe investi g
n (eg, autop
ous adverse 
gan immedia t
ils can be fo u
relevant All
maintain in h i
ments from c
rgan with a c
rse event for m
edications a d
elevant clini
se and relev a
xplanation(s )
was not rel a
orm the gov e
ons, and the 
cacy Asses
ers that enc o
gnal of effic agator must s u
sy reports a n
event, the i n
tely by fax o
und on pag e
ergan perso n
is/her files a
colleagues w
complete, w r
m describin g
dministered, 
cal informa t
ant clinical l a
) for the cau s
ated to the u s
erning IRB o
governing h
sments 
ompass visu a
acy, as follo w
51 upply Allerg
nd discharg e
nvestigator 
or email usi
e 1 of the se
nnel contact s
ll pertinent 
who assiste  
ritten descri p
g the event c
procedures 
tion about t
aboratory te
sality which 
se of the inv
of the serio u
health autho
al function 
ws: Protoco
an and the I
e summaries
must: 
ng the serio u
rious advers
s are also o n
medical rec
d in the treat m
ption of the 
chronologic
performed) 
he event:  si
sts, etc.  Inc
 includes a s
estigational 
us adverse e v
rities. 
will be eval ul RST-001-CP
RB with an y
).  
us adverse e v
e event for m
n the front p a
ords, inform a
ment and fo l
adverse eve n
ally, includi n
for the adv e
gns, sympto m
lude any ad d
statement as 
drug. 
vent as requ i
uated in the s-0001 Amend m
y additional 
vent form 
m); phone 
age of proto c
ation, and 
llow-up of t h
nt(s) on the 
ng any treat m
erse event(s)
ms, diagnos i
ditional or 
to whether t
ired by the I R
study eye in ment 2
col. 
he 
ment 
.  
is, 
the 
RB, 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 10
10.1 
A repres e
the exte
purpose, 
represen
review, 
investig
and ques
10.2 
The studpatient h
 11
11.1 
The pri
11.2 
11.2.1  Clin
Mon
entative of t
nt and natur
design, co
tatives of Al
audit and co p
ator(s) and a
tions. 
Stu
y can be ter
as complete
Dat
Prim
mary endpoi
SecoMeaical Moni t
itorin g  
he sponsor w
e of monitor i
mplexity, bli n
lergan or re g
py study-rel a
ppropri ate st
dy and Sit e
minated at a n
d study visi t
a Anal ysis 
mary (Safe t
nt is safety a
ndary End
sures of Ctoring Stru
will monitor 
ing will be b
nding, size, a
gulatory aut h
ated docum e
taff at mutu a
e Closure
ny time. Th e
ts and asses s
and Stati s
ty) Endp o
t 6 months, a
dpoints 
Change in V
52 ucture 
the study o n
based on co
and endpoin
hority repre s
ents. These r e
ally conveni
e study will b
sments.  
stical Con
oint 
as assessed 
Visual fuProtoco
n a periodic b
nsiderations s
ts of the stu
sentatives w i
epresentati
ent times to 
be consider
sideratio n
by 
nction  l RST-001-CP
basis. The d
such as the o
dy. Authoriz
ill conduct o
ves will mee t
discuss stu d
ed complete 
ns -0001 Amend m
eterminatio n
objective, 
ed 
on-site visits
t with the 
dy-related d a
after the fi nment 2
n of 
 to 
ata 
nal 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
53 11.3 Statistical Analysis Plans 
Summary tables and listings of data will be provided per Statistical Analysis Plan. All summaries 
of categorical data will present frequencies and percentages. All summaries of continuous data 
will present the number of non-missing values, mean , standard deviation, minimum, median and 
maximum. 
11.3.1  Power and Sample Size Considerations  
The sample size for this study was chosen empiri cally; no formal sample size computations to 
meet power requirements were made. The sample size of approximately 3 patients for each dose group in Phase 1 are typical for dose escalati on studies, an additional up to approximately12 
patients will be enrolled in Phase 2a fo r further safety and efficacy evaluation. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
13.1.2  
• S
i
 14
The spofor any r
closed 
w
closure 
The inve
and suffi
Reasons 
not lim
it
• Fl
• I
• Sou
ource docu
ntegrity of t
Stu
nsor designe
eason.  Stu
hen all requ
visit has bee
stigator ma
cient notice 
for the earl
ed to: 
ailure of th
ocal health 
nadequate r
Discontinuatrce Docu m
ments provi d
he data colle
dy Termin a
e reserves t h
dy sites will b
ired docum e
n performed .
y initiate stu d
is given in a
y closure of a
e investigato r
authorities, t h
ecruitment o f
ion of furth ements 
de evidence f
cted. Sourc e
ation 
he right to cl o
be closed u p
ents and stu d
. 
dy-site clos u
advance of t h
a study site b
r to comply 
he sponsor’ s
f patients by
er study trea t
56 for the exist
e documents 
ose the stud
pon study co
dy supplies 
ure at any ti
he intended 
by the spon s
with the pr o
s procedures ,
y the investi
tment devel oProtoco
ence of the 
are filed at 
y site or ter
mpletion. A 
have been c
me, provide
termination
sor or invest
otocol, the r e
, or GCP gu i
gator 
opment l RST-001-CP
patient and s
the investig a
minate the s t
study site i s
ollected and 
d there is re a
. 
igator may i n
equirements 
idelines -0001 Amend m
substantiate t
ator’s site. 
tudy at any t
s considered 
a study-site 
asonable ca u
nclude but a
of the IRB oment 2
the 
time 
use 
are 
or 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 15
15.1 
This sec
(http://cl
The goal
or incre a
possible effective
harm for 
purpose 
the scie
n
The ethinotoriou
withheld of the di
studies. 
Some
 of 
include: 
• 
• 
• 
• 
• 
Using th
guiding 
• S
• S
• F
• FReg
Ethi
tion has bee
inicalcenter.
 of clinical ses underst
to secure th
, for examp
the good o  
of ethical g
ce. 
cal guidelin
s of which i
from 400 
sease. Vario
the influent
Nuremberg 
Declaration 
Belmont Rep
CIOMS (200
U.S. Commo
ese sources 
the conduct 
ocial and cl
cientific valair patient
 s
avorable risulator y an
cal Cond u
n extracted f
nih.gov/rec r
research is t o
anding of hu m
at knowledg
le, is to test i
fothers, clin
uidelines is b
es in place t o
n America w
African Ame r
us ethical g u
ial codes of 
Code (1947) 
of Helsinki (
ort (1979) 
2) 
n Rule (199
of guidance 
of ethical re s
inical value 
idity 
election 
k-benefit ra td Ethical 
uct of the S
from the NI H
ruit/ethics.h t
o develop g e
man biolog y
e. The path t
it on patient 
ical researc h
both to prote
oday were p r
was an exper i
rican men w i
uidelines we r
ethics and r e
2000) 
1) 
and others, s
search: 
tio 
57 Consider
Study 
H guidance o
tml): 
eneralizable 
y. People w
to finding o
volunteers. 
h has the pot
ct patient v
rimarily a re
iment in Tu s
ith syphilis 
re develope d
egulations t h
seven main pProtoco
ations 
on Ethics in 
knowledge 
ho participat e
ut if a new 
But by plac
ential to ex p
olunteers an
sponse to p
skegee, Ala
so that scie
d in the 20t  
hat guide et
principles hl RST-001-CP
Clinical Re s
that improv e
e in clinical 
drug or treat m
ing some pe o
ploit patient v
d to preserv e
ast abuses, t h
bama, in whi
ntists could s
h century in r
hical clinical
ave been de s-0001 Amend m
search 
es human he
research m a
ment is safe 
ople at risk o
volunteers. T
e the integri t
he most 
ch treatmen t
tudy the co u
response to s
l research 
scribed as ment 2
alth 
ake it 
or 
of 
The 
ty of 
t was 
urse 
such 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
58 • Independent review 
• Informed consent 
• Respect for potential and enrolled patients 
Social and clinical value 
Every research study is designed to answer a spec ific question. Answering certain questions will 
have significant value for society or for present or future patients  with a particular illness. An 
answer to the research question should be important or valuable enough to justify asking people 
to accept some risk or inconvenience for others. In other words, answers to the research question 
should contribute to scientific understanding of health or improve our ways of preventing, 
treating, or caring for people with  a given disease. Only if soci ety will gain useful knowledge — 
which requires sharing results, both negative a nd positive — can exposing human patients to the 
risk and burden of research be justified. 
Scientific validity 
A study should be designed in a way that will get an understandable answer to the valuable 
research question. This includes considering whether the question researchers are asking is 
answerable, whether the research methods are valid and feasible, and whether the study is 
designed with a clear scientific objective and using accepted principles, methods, and reliable 
practices. It is also important that statistical plan s be of sufficient power to definitively test the 
objective, for example, and for data analysis. Invalid  research is unethical because it is a waste of 
resources and exposes people to risk for no purpose. 
Fair patient selection  
Who does the study need to include, to answer th e question it is asking? The primary basis for 
recruiting and enrolling groups and individuals should be the scient ific goals of the study — not 
vulnerability, privilege, or other factors unrelated to the purposes  of the study. Consistent with 
the scientific purpose, people s hould be chosen in a way that minimizes risks and enhances 
benefits to individuals and society. Groups and individuals who accept the risks and burdens of 
research should be in a position to enjoy its benefits, and those who ma y benefit should share 
some of the risks and burdens. Specific groups or  individuals (for example, women or children) 
should not be excluded from the opportunity to pa rticipate in research without a good scientific 
reason or a particular su sceptibility to risk. 
Favorable risk-benefit ratio  
Uncertainty about the degree of risks and benefits  associated with a drug, device, or procedure 
being tested is inherent in clinical research — otherwise there would be little point to doing the 
research. And by definition, there is more uncerta inty about risks and benefits in early-phase 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
research 
trivial or 
(death, d
(for exa
this stud y
research to indivi
d
Indepen
To mini
even sta
review t
sufficien
been eth
evaluati
boards (
while it 
 16
16.1 
The inve
Impleme
Protocol 
required.
 17
Allergan 
composi
personn
involves 
final rep o
 18
A final rthan in late
serious, mi
isability, in
mple, discri
y, reasonabl
patients, to 
duals and so
dent revie
mize potenti
rts, an indep
he proposal 
tly free of b
ically desig
on of resear c
IRBs), and 
is ongoing. 
Man
Prot
stigator wil
ntation of c
Amendmen
 
Pub
as the spon
tion will ref
el. Authorsh
multiple ce
ort of the m u
Spo
eport will br research. D
ght cause tr a
fection), psy c
mination or s
e efforts ha v
maximize t h
ciety are pr o
w 
al conflicts o
endent revie
and ask imp o
ias? Is the s t
ned and is th e
h projects i s
Data Safety M
agement o
ocol Ame n
l conduct th e
hanges to th e
t(s) by the s p
lication P o
sor, has pro p
lect joint co o
ip will be es t
nters, no in d
ulticenter st u
nsor's Fin a
e prepared b yDepending o n
ansient disc o
chological ( d
stigma from 
ve been take n
he potential b
oportionate t
of interest a n
w panel wit h
ortant quest i
tudy doing a
e risk– benef
s done throu g
Monitoring C
of Protoc o
ndments 
e study in ac c
e protocol w
ponsor, inve
olicy 
prietary inte r
operation be t
tablished pr i
dividual pub l
udy except a
al Report
y the spons o
59 n the particu
omfort or lo
depression, a
participatin
n to minimi
benefits, an
to, or outwe
nd make sur e
h no vested i
ions, includ
ll it can to p
fit ratio favo
gh granting a
Committees
ol Amend
cordance w i
will only be 
stigator, Ins t
rest in this s
tween multi p
ior to the wr
lications wil
s agreed wi
or. Protoco
lars of a stu
ng-term cha
anxiety), ec
g in a certai n
ze the risks a
d to determi
igh, the risk
e a study is e
interest in t
ing: Are tho s
rotect resea
rable? In th
agencies, lo c
. These gro
ments and 
ith this Clin i
made follow i
titutional R
tudy. Autho r
ple investig a
iting of the 
l be allowe
th Allergan.l RST-001-CP
dy, research 
nges. Risks c
onomic (job 
n study). Pri o
and inconve n
ne that the p o
s.  
ethically ac c
he particular 
se conducti n
rch volunte e
e United St a
cal instituti o
ups also mo n
Deviatio n
ical Study P r
ing review a
eview Boar d
rship and m a
ators and sit e
manuscript. A
d prior to co m-0001 Amend m
risks might 
can be physi
loss), or so c
or to initiati n
nience to 
otential ben e
ceptable bef o
study shou l
ng the study 
ers? Has the 
ates, indepe n
onal review 
nitor a study 
ns  
rotocol. 
and approva l
d and the FD A
anuscript 
es and Aller g
As this stud y
mpletion of tment 2
be 
cal 
cial 
ng 
efits 
ore it 
ld 
study 
ndent 
l of 
A, as 
gan 
y 
the 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 19
Blacklo w
Proc Na t
Carter P
2000;6:1
Daiger S
pigment
Dorn JD
motion 
Ophthal
Flotte T
1995;2:3
Jabs DA
Wor
king
First Int e
Klein M ,
degenerOphthal
Muzycz
PM, eds.
Nussenb
activity i
Rayapu
pigment
Schnepp 
associat
Sohocki 
Prevalen
Mutat. 2Refe
w NR, Hogg
l Acad Sci 
J, Samulski 
7-27. 
P, Bowne S
osa. Arch O
, Ahuja AK, 
by blind subj
mol. 2013;1
R, Carter BJ
57-362. 
, Nussenbla
, G. Standar
ernational 
, Birch DG. 
ative disease
mol. 2009;1
ka N, Berns 
 Fields Viro
latt RB, Pal
n intermedi
di S, Schwar
osa. 2013. C
BC, Jensen 
ed virus gen
MM, Daige
ce of mutati
001;17:42-5rences 
an MD and R
USA. 1967; 5
RJ. Adeno- a
J, and Sulli v
phthalmol. 2
Caspi A, d a
ects with th e
31:183-189. 
. Adeno-ass o
tt RB, Rose n
dization of u
Workshop. A m
Psychophys
s (RDDs) w i
19:217–224. 
KI. Parvovi r
logy. Philad e
estine AG, C
ate and post e
tz SG, Wan g
ochrane Da t
RL, Chen C
omes isolate d
r SP, Bown e
ons causing 
1. Rowe WP. I s
58:1410-141 5
associated vi r
an LS. Pers p
007;125:15
a Cruz L, Da g
e epiretinal 6
ociated viru s
nbaum JT, a n
uveitis nom e
m J Ophthal m
ical assess m
ith the Diag n
ridae: the vi r
elphia: Lipp
Chan C, Rob e
erior uveitis .
g X, and Ch a
tabase Syst R
CL, Johnson 
d from hum a
 SJ, Rodriq u
retinitis pig m
60 solation of 
5. 
ral vectors 
pective on g e
1-158. 
gnelie G, S
60-electrod
s vectors for 
nd Standard i
enclature fo  
mol. 2005;1
ment of low 
nosys full-fi
ruses and th
incott Willi a
erge F. Stan d
. Ophthalm
avis P.  Vita m
Rev 12, CD
PR and Cla r
an tissues. J 
uez JA, Nor t
mentosa anProtoco
adeno virus-
as gene deli
enes and m
ahel JA, gus ,
e (argus II) r
gene thera
ization of U
r reporting c l
40:509-516.
visual functi
eld stimulu
eir replicati o
ams & Wilk
dardization 
ology. 1985; 9
min A and fi s
008428. 
rk KR. Cha r
Virol. 2005
thrup H, He
d other inhe rl RST-001-CP
associated v i
very vehicle s
utations cau s
, I.I.S.G. Th e
etinal prost h
py. Gene Th e
veitis Nome n
linical data. 
on in patien t
s threshold ( D
on. In: Knip e
ins, 2001:23
of vitreal in f
92:467–471 .
sh oils for r e
racterization 
;79:14793-1
ckenlively J R
rited retinop a-0001 Amend m
iruses from m
s. Int J Mol M
sing retinitis 
e detection o
hesis. JAM A 
er. 
nclature 
Results of t h
ts with retin a
D-FST). Do
e DM, How l
27-2359. 
flammatory 
. 
etinitis 
of adeno 
4803. 
R, Sullivan L
athies. Hum ment 2
man. 
Med. 
of 
A
he 
al 
c 
ley 
LS. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
 20
20.1 
AE  
AST 
BCVA 
oC 
CFR 
CRF 
CTC 
DLT 
DNA 
DSMC 
ETDRS 
FDA 
FIH 
GCP 
GLP 
GMP 
IND 
IOP 
IRAE 
ISCEV 
mm 
NEI 
NIH 
QoL 
RGC 
RP 
RST-001 
USA 
VFQ 
 App
Appendices 
endix 1: A
Adverse Ev e
Aspartate a m
Best Correc t
Degrees Cel
Code of Fe d
Case Report 
Common T e
Dose Limiti n
Deoxyribon u
Data Safety 
Early Treat m
Food and D r
First-in-Hu m
Good Clinic
Good Labor a
Good Manu f
Investigatio n
Intraocular P
Immediatel y
Internationa l
Millimeters 
National Ey e
National Ins t
Quality of L
Retinal Gan g
Retinitis Pi g
RetroSense 
United Stat e
Visual Func tAbbreviati o
ent 
minotransferas e
ted Visual Ac u
sius 
deral Regulatio n
Form 
erminology Cr i
ng Toxicity 
ucleic Aci d 
Monitoring C o
ment for Diabe t
rug Administr a
man 
al Practice 
atory Practice
facturing Prac t
nal New Drug
Pressure 
y Reportable A
l Society for C
e Institute 
titutes of Heal t
ife 
glion Cells 
gmentosa 
Therapeutics d
es of America 
tioning Questi o
61 ons 
e 
uity 
ns 
iteria for Adve
ommittee 
tic Retinopath y
ation, USA 
tice 
dverse Even t 
Clinical Electro
th 
drug product (
onnaire Protoco
rse Events 
y Stud y 
physiology of 
AGN-151597)l RST-001-CP
Vision -0001 Amend mment 2
